NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) CEO Joel Becker bought 11,891 shares of the company's stock in a transaction on Tuesday, November 17th. The stock was bought at an average cost of $8.35 per share, for a total transaction of $99,289.85. Following the completion of the acquisition, the chief executive officer directly owned 149,891 shares of the company's stock, valued at approximately $1,251,589.85. This represents a 8.62% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
NeuroPace Stock Up 2.9%
Shares of NASDAQ NPCE traded up $0.23 during trading on Tuesday, reaching $8.20. The company had a trading volume of 684,069 shares, compared to its average volume of 219,143. NeuroPace, Inc. has a 12-month low of $5.46 and a 12-month high of $19.60. The stock has a market cap of $281.42 million, a PE ratio of -14.64 and a beta of 1.98. The business's 50-day moving average is $13.07 and its 200 day moving average is $14.71. The company has a quick ratio of 3.91, a current ratio of 4.94 and a debt-to-equity ratio of 4.97.
Analyst Ratings Changes
A number of equities research analysts have recently commented on NPCE shares. KeyCorp cut their price target on shares of NeuroPace from $18.00 to $14.00 and set an "overweight" rating on the stock in a report on Friday. Leerink Partners lowered shares of NeuroPace from an "outperform" rating to a "market perform" rating and set a $7.00 price objective for the company. in a report on Friday. Cantor Fitzgerald decreased their price objective on shares of NeuroPace from $21.00 to $12.00 and set an "overweight" rating for the company in a report on Friday. Wells Fargo & Company cut NeuroPace from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $19.00 to $9.00 in a research report on Friday. Finally, Mizuho cut their target price on NeuroPace from $22.00 to $12.00 and set an "outperform" rating on the stock in a research note on Monday. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $13.11.
Check Out Our Latest Stock Analysis on NeuroPace
Hedge Funds Weigh In On NeuroPace
A number of hedge funds have recently bought and sold shares of NPCE. Legal & General Group Plc bought a new position in NeuroPace during the 2nd quarter valued at about $41,000. Entropy Technologies LP bought a new stake in shares of NeuroPace in the third quarter worth approximately $146,000. Diversified Trust Co purchased a new position in shares of NeuroPace during the third quarter valued at approximately $153,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of NeuroPace during the second quarter valued at approximately $157,000. Finally, Bank of America Corp DE purchased a new position in shares of NeuroPace during the second quarter valued at approximately $322,000. Hedge funds and other institutional investors own 78.83% of the company's stock.
NeuroPace News Summary
These are some of the NPCE news items that stood out recently:
- Positive Sentiment: HC Wainwright and Cantor Fitzgerald lowered their targets from $20 and $21, respectively, to $12, while retaining Buy and Overweight ratings. Their revised targets imply considerable upside, though the cuts reflect a more cautious outlook. HC Wainwright analyst recommendation Cantor Fitzgerald analyst recommendation
- Neutral Sentiment: NeuroPace’s discounted valuation and the growth potential of its RNS system are cited as opportunities, but the article says weak implant activity, execution challenges and regulatory risks complicate the outlook. Zacks analysis of growth potential and execution risk
- Negative Sentiment: Analyst sentiment has weakened: Wolfe Research cut its rating from Strong Buy to Hold, while Wall Street Zen moved its rating to Sell. JPMorgan downgraded the stock to Neutral and Leerink Partners to Market Perform. Wolfe Research recommendation Wall Street Zen rating
NeuroPace Company Profile
(
Get Free Report)
NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.